WO2012064130A3 - 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물 - Google Patents

대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물 Download PDF

Info

Publication number
WO2012064130A3
WO2012064130A3 PCT/KR2011/008571 KR2011008571W WO2012064130A3 WO 2012064130 A3 WO2012064130 A3 WO 2012064130A3 KR 2011008571 W KR2011008571 W KR 2011008571W WO 2012064130 A3 WO2012064130 A3 WO 2012064130A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
celecoxib
treating
pharmaceutical composition
active ingredient
Prior art date
Application number
PCT/KR2011/008571
Other languages
English (en)
French (fr)
Other versions
WO2012064130A2 (ko
Inventor
정연진
김영미
이용현
Original Assignee
부산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부산대학교 산학협력단 filed Critical 부산대학교 산학협력단
Publication of WO2012064130A2 publication Critical patent/WO2012064130A2/ko
Publication of WO2012064130A3 publication Critical patent/WO2012064130A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Abstract

본 발명은 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물에 관한 것으로, 보다 상세하게는 대장성 질환의 치료 또는 예방에 COX-2 저해제인 셀레콕시브를 활용하기 위하여 위 및 소장에서는 흡수되지 않고 안정한 상태로 존재하며, 대장에서 효소에 의해 대사되어 약리효과를 발휘할 수 있는 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물에 관한 것이다.
PCT/KR2011/008571 2010-11-11 2011-11-10 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물 WO2012064130A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100112171A KR101245078B1 (ko) 2010-11-11 2010-11-11 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
KR10-2010-0112171 2010-11-11

Publications (2)

Publication Number Publication Date
WO2012064130A2 WO2012064130A2 (ko) 2012-05-18
WO2012064130A3 true WO2012064130A3 (ko) 2012-07-19

Family

ID=46051437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008571 WO2012064130A2 (ko) 2010-11-11 2011-11-10 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물

Country Status (2)

Country Link
KR (1) KR101245078B1 (ko)
WO (1) WO2012064130A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CN107540726A (zh) * 2017-08-22 2018-01-05 河北科技大学 一类肽基塞来昔布衍生物及其应用
CN113144212B (zh) * 2021-03-15 2022-02-11 上海英诺富成生物科技有限公司 一种塞来昔布的前体药物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255087A1 (en) * 2007-04-04 2010-10-07 Ivan Coulter oral pharmaceutical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092566A1 (en) * 2002-11-12 2004-05-13 Graneto Matthew J. Celecoxib prodrug
ES2337915T3 (es) * 2004-10-27 2010-04-30 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugados con adtividad antiinflamatoria.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255087A1 (en) * 2007-04-04 2010-10-07 Ivan Coulter oral pharmaceutical composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PRABHAT K. SHRIVASTAVA ET AL.: "Dextran carrier macromolecular for colon specific delivery of celecoxib", CURRENT DRUG DELIVERY, vol. 7, no. 2, April 2010 (2010-04-01), pages 144 - 151 *
V. R. SHINHA ET AL.: "Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer", DRUG DELIVERY, vol. 13, no. 3, 2006, pages 221 - 225 *
Y.S.R. KRISHNAIAH ET AL.: "In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers", EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, vol. 27, no. 4, 2002, pages 273 - 280 *
YUBJIN JUNG ET AL.: "What should be considered on design of a colon-specific prodrug?", EXPERT OPINION ON DRUG DELIVERY, vol. 7, no. 2, February 2010 (2010-02-01), pages 245 - 258 *

Also Published As

Publication number Publication date
WO2012064130A2 (ko) 2012-05-18
KR20120050759A (ko) 2012-05-21
KR101245078B1 (ko) 2013-03-18

Similar Documents

Publication Publication Date Title
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
MY183312A (en) Pharmaceutical formulation
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2014002058A3 (en) Complement pathway modulators and uses thereof
WO2009032034A3 (en) Stabilized picoplatin dosage form
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
MX2011012122A (es) Derivados de tiofeno.
WO2014009833A3 (en) Complement pathway modulators and uses thereof
IN2015DN00137A (ko)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
BR112013017302A2 (pt) formulações de imunossupressor
WO2010129057A3 (en) Tetracycline compounds
PH12014501408A1 (en) Immediate release multi unit pellet system
MY163762A (en) Therapeutic agent for chronic renal failure
WO2014036502A3 (en) Tetracycline compounds
WO2009060952A1 (ja) 新規製剤
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2012064130A3 (ko) 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
MX2010000693A (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto.
EP2101742B8 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
WO2014065640A3 (ko) 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물
UA107716C2 (ru) Терапевтическое средство с замедленным высвобождением на основе соединения 2-фенилтиазола для гипертонии и почечной дисфункции
WO2009043577A3 (de) 19-nor-progesterone zur kontrazeption

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11840364

Country of ref document: EP

Kind code of ref document: A2